Forthcoming Events
and information for sponsors

europe-slais.org
About SLAS

SLAS is the Society for Laboratory Automation and Screening – a global community of more than 20,000 life sciences discovery and technology professionals including scientists, innovators, researchers, academics and students, engineers, informatics specialists and business leaders. We unite great minds in science and technology for the advancement of research, using the power of technology to achieve scientific objectives.

What we do

Every day, SLAS members exchange ideas, insights and answers to help tackle challenges old and new. Our year-round programme of networking, forums and education provides the resources, unique access and peer connections to stay on top of it all.

SLAS works to advance scientific discovery and technology through education, research, and by serving as a public forum for the exchange of information related to laboratory science and technology.

Our members

SLAS members have a diverse range of science and technology interests including:

- drug discovery
- assay development and screening
- laboratory automation and high-throughput technologies
- micro- and nano technologies
- molecular diagnostics and biomarkers
- scientific informatics
- bioanalytical techniques
- drug target biology

SLAS Europe

The SLAS Europe office organises networking, educational and training events to support the connectivity and career development of scientists interested in laboratory automation and screening across the region.
Why take part in an SLAS event?

Learn from the experts

SLAS events feature experts and key opinion-formers from the worlds of research, academia and industry. You’ll hear the latest evidence-based information on best practice, and be able to meet with these experts face-to-face.

Participate in exclusive tutorials

Many SLAS events are complemented by hands-on tutorials that give you the opportunity to learn how to use instruments or develop your expertise in data analysis.

Gain industry intelligence and build collaborations

You will discover who is at the forefront of the sectors you are working in, including potential partners for collaboration.

Keep your skills up to date

In the fast-moving world of research and technology, it's vital that your skills remain up to date. At SLAS events you’ll be brought up to date with emerging technologies and processes, and will be the first to hear about emerging trends in your sector.

Build your networks

Discover who’s who in the European and global scientific community and build a network of trusted peers who can help you achieve your personal and professional goals.

Showcase your research

Deliver podium presentations, author posters and take part in prestigious scientific competitions, enabling you to showcase your research to an international audience.
**Why exhibit at an SLAS event?**

Exhibitors at SLAS events enjoy unrivalled opportunities to showcase their products, services and technologies; and identify new customers. Exhibiting at an SLAS event enables a company to:

- attract leads
- build one-to-one relationships with customers and prospects
- raise awareness
- launch new products
- showcase their brands
- create goodwill
- expand their customer base

Most delegates at SLAS events are decision-makers with decades of industry experience. A smaller proportion are made up of students and more junior employees: the decision-makers of the future. You’ll get to meet and network with all these groups, with multiple opportunities to promote your brand, identify new customers and fortify existing industry relationships.

### Delegates: level of experience

<table>
<thead>
<tr>
<th>Experience Level</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>0–5 years</td>
<td>4%</td>
</tr>
<tr>
<td>5–10 years</td>
<td>19%</td>
</tr>
<tr>
<td>10–20 years</td>
<td>27%</td>
</tr>
<tr>
<td>20+ years (decision makers)</td>
<td>39%</td>
</tr>
<tr>
<td>Students</td>
<td>11%</td>
</tr>
</tbody>
</table>

### Top areas of interest

- **67%** Drug discovery
- **49%** Drug target biology
- **34%** Laboratory automation and high-throughput technologies
- **22%** Compound management
- **13%** Scientific informatics
- **6%** Assay development and screening

### Delegates: job titles

- **Academia – Faculty/Researcher**: 17%
- **Academia – Post-Doctoral**: 5%
- **Executive Management**: 4%
- **Industry Scientist/Researcher/Engineer**: 48%
- **Management**: 16%
- **Sales/Marketing/Business Development**: 10%

### Top company/organizational affiliation of SLAS attendees

- **Pharmaceuticals & Biopharmaceuticals**: 52%
- **Academia/Institute**: 29%
- **Product and Service Providers**: 14%
Forthcoming events

High-Content Screening Conference
27–29 June 2016 | Dresden, Germany

This conference gathers researchers, academics and industry professionals working in High-Content Screening to explore the latest advances and emerging technologies in the field. Hot topics include novel organisms, novel markers, new essays, novel microscopy techniques, image analysis and statistics.

VIII Spanish Drug Discovery Network Meeting
3–4 November 2016 | Santiago de Compostela, Spain

This international meeting continues to be the ideal forum for drug discovery and chemical biology professionals to discuss the frontline of chemical biology, drug discovery and translational medicine research. This year, the programme focuses on the use of more predictive model systems throughout the discovery process, from early primary screening and moving towards preclinical and clinical studies.

Translating Research Ideas into Future Therapeutics Conference
29–30 November 2016 | Leuven, Belgium

Designed to engage academic scientists, pharma open innovation groups, infrastructure providers, CROs and funders from across Europe, the Translating Research Ideas into Future Therapeutics Conference enables emerging and exciting novel drug targets from academia to progress further along the drug discovery pipeline.
Translating Research Ideas into Future Therapeutics Conference
29–30 November 2016 | Leuven, Belgium

Designed to engage academic scientists, pharma open innovation groups, infrastructure providers, CROs and funders from across Europe, the Translating Research Ideas into Future Therapeutics Conference enables emerging and exciting novel drug targets from academia to progress further along the drug discovery pipeline.

The organising committee of this meeting is assembling an exciting and comprehensive Conference programme including:

- plenary talks showcasing success stories
- sessions from pharma open innovation organisations and VCs outlining offerings and expectations
- presentations from CROs/infrastructure providers staging available platforms and collaboration opportunities
- pitches from academic scientists or project holders, presenting on project concept, current status, proposed next steps and expectations for collaboration/funding
- poster sessions
- networking events
- one-to-one meetings

Scientific Committee

David Cronk CBiol MRSB, Director, Hit Discovery Charles River Laboratories
Dr. Philip Gribbon, Chief Scientific and Operational Officer European ScreeningPort, Fraunhofer IME ScreeningPort
Catherine Kettleborough Ph.D., Head of Biology, MRCT Centre for Therapeutics Discovery, Stevenage Bioscience Catalyst
Hugo Klaassen, Manager High Throughput Screening, Cistim
Dr. Eberhard Krausz, Expert, Discovery Biology, VIB Discovery Sciences Labs

Call for Projects – Highlight Your Project’s Aims, Achievements and Needs

In front of an audience of VCs, Pharma Open Innovation groups and government funding organisations, project holders from academia and start-ups will have an opportunity to present the key scientific findings underlying their existing therapeutic asset and receive clear direction to achieve successful results.

The deadline for submission of projects is Friday, 16 September 2016. For more information about submission guidelines please visit europe-slas.org.
The 8th Spanish Drug Discovery Network Meeting is focused on the use of more predictive model systems throughout the discovery process, from early primary screening and moving towards preclinical and clinical studies. The presentations and discussions include:

- the establishment and validation of advanced phenotypic model systems such as organoids
- the intelligent choice of small molecule screening libraries to facilitate identification of important mechanisms in these systems
- the latest methodologies for mechanism studies and target identification downstream of phenotypic screening
- the progress towards more predictive animal models both from an efficacy and safety perspective

The program covers a broad range of technologies applied in phenotypic screening and learning experiences from the establishment and use of primary cells and organoids in the screening cascades. During the meeting the discussion will evolve from isolated primary cells towards more advanced and predictive animal models. This is an excellent opportunity to build relations with experts that have invested time in these fields and to understand the paths they have taken.

"This is a great opportunity to meet, interact with and learn from people interested in chemical biology and drug discovery and their progress towards more complex and predictive model systems early on in the discovery process. It takes a focused view on the entire process and will discuss the use of such models and the efforts required to profit from these."
Sponsors from previous SLAS events

Agilent Technologies
Bio Ascent
Blue Cat Bio
BMG LabTech
Cellectricon
CENIBRA
Corning
Dedicated to People.
inSphero
HighRes Biosolutions
LVL Technologies
Molecular Devices
MolPort
PerkinElmer
Promega
Lab Services
LabTec Diagnostics
SPIROCHROME
STORAGE
LABCYTE
Spirochamps
Tebu-Bio
Tecan
Xavo
Y-Med Biotech
Cisbio
AstraZeneca
HIDEX
Innoprot
Liberate Technologies
Mockingbird
I&L Biosystems
Interface